Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients

Thrombosis and Haemostasis

Volumn 93, Issue 6, 2005, Pages 1185-1188

  Kovacs, Michael J ^a   Levine, Mark N ^b   Keeney, Michael ^a   MacKinnon, Karen M ^a   Lee, Agnes Y ^b  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Anti Xa levels; Cancer; Low molecular weight heparin; VTE

Indexed keywords

ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; FEMALE; HUMAN; LONG TERM CARE; LUNG EMBOLISM; MALE; MAXIMUM PERMISSIBLE DOSE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; DALTEPARIN; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; THROMBOEMBOLISM; WARFARIN;

EID: 20444492385     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-01-0052     Document Type: Article

References (13)

1. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119(1 Suppl): 176S-193S.
2. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-62.
3. Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
4. Levine M, Gent M, Hirsch J et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 667-81.
5. Wells PS, Kovacs MJ, Bormanis J et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158: 1809-12.
6. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002; 87: 163-4.
7. Prandoni P, Lensing AW, Piccioli A et al. Recurrent venous thromboembolisin and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-88.
8. Siguret V, Pautas E, Fevrier M et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84: 800-04.
9. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998;79: 1162-65.
10. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S.
11. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.
12. Kitchen S, Iampietro R, Woolley AM et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-93.
13. Kovacs MJ, Keeney M, MacKinnon K et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 1999; 21: 55-60.